We are live on ! Find out more
AEON.WS

AEON Biopharma Inc
AEON.WS

Delisted

AEON.WS was delisted on the 26th of April, 2024.

Back to rankings

30 hedge funds and large institutions have $3.62M invested in AEON Biopharma Inc in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

482% more capital invested

Capital invested by funds: $623K → $3.62M (+$3M)

25% less funds holding

Funds holding: 40 → 30 (-10)

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 10

Holders
30
Holders Change
-10
Holders Change %
-25%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
9
Closed
10
Calls
$271K
Puts
–
Net Calls
+$271K
Net Calls Change
+$246K

Top Buyers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
+$62.5K
2
UBS Group
UBS Group
Switzerland
+$2.46K
3
Jane Street
Jane Street
New York
+$223

Top Sellers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
-$119K
2
SCM
Shaolin Capital Management
Florida
-$91.6K
3
PC
Periscope Capital
Ontario, Canada
-$82.5K
4
CF
Cantor Fitzgerald
New York
-$59.6K
5
CS
Clear Street
New York
-$27.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
DKCM
1
Davidson Kempner Capital Management
New York
$532K – – –
LP
2
LMR Partners
United Kingdom
$362K – – –
AC
3
Athos Capital
Hong Kong
$295K – – –
WAM
4
Wolverine Asset Management
Illinois
$274K +$62.5K +101,956 +117%
AC
5
Aristeia Capital
Connecticut
$250K -$119K -194,078 -54%
TCM
6
Tenor Capital Management
New York
$242K – – –
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$224K – – –
QGA
8
Q Global Advisors
Texas
$192K -$613 -1,000 -0.8%
Hudson Bay Capital Management
9
Hudson Bay Capital Management
Connecticut
$145K – – –
WA
10
Whitebox Advisors
Minnesota
$133K – – –
Calamos Advisors
11
Calamos Advisors
Illinois
$121K – – –
Goldman Sachs
12
Goldman Sachs
New York
$115K – – –
UOC
13
UBS O'Connor
Illinois
$114K – – –
KL
14
KIM LLC
Kansas
$91.9K -$12.3K -19,975 -24%
SC
15
Sculptor Capital
New York
$76.3K – – –
DCM
16
Dupont Capital Management
Delaware
$72.5K – – –
FCM
17
Farallon Capital Management
California
$72.5K – – –
Jane Street
18
Jane Street
New York
$59.2K +$223 +363 +0.9%
Walleye Capital
19
Walleye Capital
New York
$57.3K -$15.6K -25,400 -39%
MCM
20
Moore Capital Management
New York
$48.3K – – –
PAMP
21
Polar Asset Management Partners
Ontario, Canada
$41.7K – – –
HF
22
HRT Financial
New York
$27K – – –
PC
23
Periscope Capital
Ontario, Canada
$22.5K -$82.5K -134,500 -90%
Parallax Volatility Advisers
24
Parallax Volatility Advisers
California
$17.6K -$7.89K -12,859 -51%
Walleye Trading
25
Walleye Trading
New York
$16.8K -$8.95K -14,600 -56%
1
2

AEON.WS Hedge Fund Activity: Q1 2024 in Review

30 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q1 2024, worth a combined $3.62M — up 482% from $623K a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of AEON.WS and 0 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 3 added.

The largest buyer was Wolverine Asset Management, adding an estimated $62.5K. The largest seller was Aristeia Capital, cutting an estimated $119K.

  • 30 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q1 2024, down from 40 in Q4 2023.
  • Funds reported $3.62M of AEON Biopharma Inc stock for Q1 2024, up 482% quarter-over-quarter.
  • 0 funds opened new AEON Biopharma Inc positions in Q1 2024 and 10 closed out, a net change of -10 holders.
  • The largest AEON Biopharma Inc buyer in Q1 2024 was Wolverine Asset Management, an estimated $62.5K added.
  • The largest AEON Biopharma Inc seller in Q1 2024 was Aristeia Capital, an estimated $119K sold.

Based on aggregated 13F filings for Q1 2024.